Objective: To evaluate the effectiveness of the fast weight loss method on liver steatosis, fibrosis, inflammation, glycemic and lipids features and body composition in patients with severe Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes (T2D). Methods: A 24-week open prospective randomised controlled clinical trial including 80 adult patients (aged 40-65 years) was performed. The patients after randomisation were divided in two groups: Main group followed the fast weight loss method; Control group received conventional drug treatment. The fast weight loss method included calorie restriction, salt intake, walking and sexual self-restraint. The conventional drug therapy included Vitamin E, Orlistat, Pioglitazone hydrochloride, Atorvastatin, Lisinopril, benzodiazepines and anti-inflammatory agents. Primary endpoints: ultrasound and histology suggestive of steatohepatitis, hepatic enzymes, weight loss, 2-hour oral glucose tolerance test, HbA1c. Secondary endpoints: blood pressure, lipids. Results: 83% patients completed the study. In Main weight lost 7-16 kg (10-20% from baseline) for 8-10 weeks. In Main weight lost due to reduction of fat mass only. Main vs. Controls showed higher decrease in fat mass from baseline (P < 0.001). Ultrasound imaging and liver histological scoring system evidenced significant improvement on liver steatosis/fibrosis in Main (P < 0.001). In Main vs. Controls weight lost at 24 weeks led to positive laboratory changes in ALT, AST, 2-hour OGTT, HbA1c, HOMA-IR, BP, cholesterol, triglycerides, bilirubin total, blood hemoglobin (P = 0.01). The fast weight loss in the patients adequately led to decrease in symptomatic drugs up to complete abolition. Conclusions: The study showed benefits of the fast weight loss method improving in steatosis/fibrosis, biochemical/metabolic outcomes in patients with severe NASH and T2D.